Sumitovant Biopharma, Inc., based in New York, NY, is dedicated to improving global health by driving innovative treatments in critical areas such as psychiatry, neurology, oncology, urology, women's health, rare diseases, and cell gene therapy. Their diverse pipeline of preclinical and clinical programs aims to address high patient needs through a technology-driven approach.
Sumitovant Biopharma, Inc., through its U.S. subsidiary, Sumitomo Pharma America, Inc., embodies a bold promise of combining technology and life-sciences expertise to deliver patient-first solutions faster and more efficiently, ultimately improving patient outcomes worldwide.
Generated from the website